BOPI 11 BR/2024 REPERTOIRE NUMERIQUE 11 (11) 21686 Consulter le mémoire (51) A61K 31/427 (2018.01); C07D 277/52 (2018.01); C07D 417/04 (2018.01); C07D 417/12 (2018.01) ; C07D 417/14 (2018.01) (21) 1202200188 - PCT/US2020/060180 (22) 12/11/2020 (30) US n° 62/934,293 du 12/11/2019 (54) 5-Membered heteroarylamino-sulfonamides for treating conditions mediated by deficient CFTR activity. (72) GAO, Zhongli (US); SMRCINA, Martin (US); HARTUNG, Ryan (US); MUNSON, Mark (US); HURLBUT, Gregory (US); LIAO, Junkai (US); BALTZER, Sylvie (US); VIVET, Bertrand (US); FREED, Brian (US); NESTLER, Hans, Peter (US); YEOMAN, Helen (US); MECHIN, Ingrid (US); MA, Nina (US); LEBRETON, Sylvain (US); WIRE, William (US) et THURAIRATNAM, Siikanthini (US) (73) GENZYME CORPORATION, 50 Binney Street, CAMBRIDGE, MA 02142 (US) (74) Cabinet Spoor & Fisher Inc. Ngwafor & Partners, The House of Gideon, Golf/Bastos Quater, Opposite The American Embassy, Entrance-Saint John Paul II Boulevard, P.O. Box 8211, YAOUNDE (CM). (57) The invention relates to heteroaryl compounds, pharmaceutically acceptable salts thereof, and pharmaceutical preparations thereof. Also described herein are compositions and the use of such compounds in methods of treating diseases and conditions mediated by deficient CFTR activity, in particular cystic fibrosis. Formula I ________________________________________ (11) 21687 Consulter le mémoire (51) A01N 25/04 (2023.01); A01N 25/06 (2023.01); A01N 25/14 (2023.01); A01N 51/00 (2023.01) ; A01P 7/04 (2023.01) (21) 1202200502 - PCT/JP2021/021595 (22) 07/06/2021 (30) JP n° 2020-099174 du 08/06/2020 (54) Controlling method for infectious disease vector. (72) NIDE, Mika (JP) et UEBAYASHI, Tsuguaki (JP) (73) Sumitomo Chemical Company, Limited, 27-1, Nihonbashi, Chuo-ku, TOKYO 1036020 (JP) (74) Cabinet Spoor & Fisher Inc. Ngwafor & Partners, The House of Gideon, Golf/Bastos Quater, Opposite The American Embassy, Entrance-Saint John Paul, II Boulevard, P.O. Box 8211, YAOUNDE (CM). (57) The present invention provides a method for controlling infectious disease vectors, which comprises diluting a formulation comprising a neonicotinoid compound having a volume mean diameter being within a range of 3 to 10 pm, a surfactant and a carrier with water; and spraying the diluted solutions to a surface to be treated such that a treated amount of neonicotinoid compound is within a range of 50 to 800 mg/m2.
RkJQdWJsaXNoZXIy MTM1NDc3MA==